Publicaciones en las que colabora con Josefina Galende del Canto (12)

2011

  1. Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study

    Leukemia Research, Vol. 35, Núm. 9, pp. 1184-1187

2001

  1. Continuous oral cytarabine ocfosfate with interferon-α-2b for patients with newly diagnosed chronic myeloid leukaemia: A pilot study

    British Journal of Haematology, Vol. 115, Núm. 3, pp. 541-544

1999

  1. In vitro growth in acute myeloblastic leukemia: Clinico-biological correlations

    Leukemia and Lymphoma, Vol. 36, Núm. 1-2, pp. 1-7

1998

  1. In vitro growth in acute myeloblastic leukaemia: Relationship with other clinico-biological characteristics of the disease

    British Journal of Haematology, Vol. 103, Núm. 1, pp. 137-142

1997

  1. In leukemic hematopoiesis CD34 antigen does not have the same significance as it does normal hematopoiesis

    Leukemia Research, Vol. 21, Núm. 7, pp. 651-656

  2. Sequential intravenous-oral ciprofloxacin plus amoxycillin/clavulanic acid shortens hospital stay in infected non severe neutropenic patients

    Hematology and Cell Therapy, Vol. 39, Núm. 5, pp. 223-227

1996

  1. ACCION DE ALGUNOS FACTORES DE CRECIMIENTO HEMATOPOYETICOS SOBRE LOS BLASTOS DE LEUCEMIA AGUDA MIELOBLASTICA

    Sangre, Vol. 41, Núm. 1, pp. 3-8

  2. Value of colony forming unit-granulocyte macrophage assay in predicting relapse in acute myeloid leukaemia

    Journal of Clinical Pathology, Vol. 49, Núm. 6, pp. 450-452

1995

  1. In vitro autonomous proliferation in ANLL: Clinical and biological significance

    Leukemia Research, Vol. 19, Núm. 6, pp. 411-416

  2. USO CLINICO ACTUAL DE LOS FACTORES DE CRECIMIENTO HEMATOPOYETICO

    Inflamacion y Regulacion del Crecimiento Celular, Vol. 6, Núm. 5, pp. 281-298

  3. USO CLINICO ACTUAL DE LOS FACTORES DE CRECIMIENTO HEMATOPOYETICO

    Inflamacion y Regulacion del Crecimiento Celular, Vol. 6, Núm. SPEC. ISS., pp. 25-41

1994

  1. Clonogenic cells of acute leukemia secondary to myeloproliferative and myelodysplastic syndromes

    Sangre, Vol. 39, Núm. 5, pp. 331-335